MedPath
HSA Approval

DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA

SIN12186P

DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA

DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA

February 6, 2003

AENON PHARMACEUTICALS SEA PTE. LTD.

AENON PHARMACEUTICALS SEA PTE. LTD.

Regulatory Information

HSA regulatory responsibility and product classification details

Regulatory Responsibility

RegistrantAENON PHARMACEUTICALS SEA PTE. LTD.
Licence HolderAENON PHARMACEUTICALS SEA PTE. LTD.

Product Classification

D
Drug Type
Therapeutic
F
Forensic Class
Prescription Only
HSA Singapore Classification

Formulation Information

SUSPENSION

**DOSAGE AND ADMINISTRATION** _Cholera_: Primary immunisation: consists of 2 doses of vaccine for adults and children over the age of 6 years. Children from 2 to below 6 years of age should receive 3 doses. Doses are to be administered at intervals of at least 1 week. If more than 6 weeks elapse between doses, the primary immunisation course should be re-started. Immunisation should be completed at least 1 week prior to potential exposure. _Booster dose_: For continuous long-term protection, a single booster dose is recommended for adults after 2 years. Children from 2–6 years of age should receive a booster dose after 6 months. _ETEC_: Primary immunisation: For adults and children consists of 2 doses of vaccine at an interval of at least 1 week. If more than 6 weeks elapse between doses, basic immunisation should be restarted. Satisfactory protection against cholera and ETEC diarrhoea can be expected about 1 week after basic immunisation is concluded. **Children below 2 years** **DUKORAL** ® has been given to children between 1 and 2 years of age in safety and immunogenicity studies, but the protective efficacy has not been studied in this age group. Therefore, **DUKORAL** ® is not recommended to be used in children below 2 years of age. **Elderly** There are only very limited data on protective efficacy of the vaccine in subjects aged 65 years and more. **Method of Administration** The vaccine is intended for oral use. Before ingestion, the vaccine suspension should be mixed with a buffer (sodium hydrogen carbonate) solution. The sodium hydrogen carbonate (buffer) is supplied as effervescent granules which should be dissolved in a glass of cool water (ca. 1.5 dl). Chlorinated water can be used. The vaccine suspension should then be mixed with the buffer solution and drunk within 2 hours. Food and drink should be avoided 1 hour before and 1 hour after vaccination. Oral administration of other medicinal products should be avoided within 1 hour before and 1 hour after administration of **DUKORAL** ®. _Children 2–6 years of age_: half the amount of the buffer solution is poured away and the remaining part (approx. 75ml) is mixed with the entire contents of the vaccine bottle.

ORAL

Medical Information

**INDICATIONS** _Cholera:_ Active immunisation of adults and children from 2 years of age who will be visiting areas with an ongoing or anticipated epidemic or who will be spending an extended period of time in areas in which cholera infection is a risk. _ETEC_: Active immunisation of adults and children from 2 years of age who will be visiting areas posing a great risk of diarrheal illness caused by enterotoxigenic _Escherichia coli_ (ETEC), one of the most common causes of “travellers’ diarrhea”. **DUKORAL** ® should not replace standard protective measures. In the event of diarrhea measures of rehydration should be instituted.

**CONTRAINDICATIONS** Hypersensitivity to the active substances, to any of the excipients or to formaldehyde. Administration of **DUKORAL** ® should be postponed for subjects suffering from acute gastrointestinal illness or acute febrile illness.

J07AE01

cholera, inactivated, whole cell

Manufacturer Information

AENON PHARMACEUTICALS SEA PTE. LTD.

Valneva Sweden AB

Recipharm Stockholm AB (Effervescent Granules)

Active Ingredients

RECOMBINANT CHOLERA TOXIN B SUBUNIT (rCTB)

1 mg/dose

VIBRIO CHOLERAE O1 OGAWA CLASSIC STRAIN (HEAT INACTIVATED)

31.25 x 10^9 bacteria

VIBRIO CHOLERAE O1 INABA CLASSIC STRAIN (HEAT INACTIVATED)

31.25 x 10^9 bacteria

VIBRIO CHOLERAE O1 OGAWA CLASSIC STRAIN (FORMALIN INACTIVATED)

31.25 x 10^9 bacteria

VIBRIO CHOLERAE O1 INABA EL TOR STRAIN (FORMALIN INACTIVATED)

31.25 x 10^9 bacteria

Documents

Package Inserts

Dukoral PI.pdf

Approved: January 14, 2016

Download

Patient Information Leaflets

Dukoral Vaccine PIL.pdf

Approved: August 1, 2013

Download

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.

DUKORAL VACCINE AGAINST CHOLERA AND ETEC-DIARRHOEA - HSA Approval | MedPath